Hi FrannyB, I'm copying/pasting their reply, but I'm not sure I can do this on a public forum.
EvorelĀ® Conti (estradiol hemihydrate & norethisterone acetate) - Cutting the
Patch
The Summary of Product Characteristics (SPC) is a more detailed document than
the Patient Information Leaflet (PIL), and is primarily written for healthcare
professionals.
The Summary of Product Characteristics (SmPC) for the Evorel range does not
make any recommendations about cutting the patch.
Evorel transdermal patches use a matrix system, which is translucent or transparent.
There is no guarantee that the hormones in the Evorel range transdermal patches
are distributed evenly throughout the patch.
Transdermal systems may be altered in both absorption and efficacy if patches are
cut, potentially putting a patient at risk.
In the absence of available efficacy and safety data, cutting of Evorel range patches
is outside the terms of the product licence, and any such use would be the
responsibility of the prescriber.
However, Doctors sometimes prescribe off-licence doses to those recommended on
the Patient Information Leaflet or Summary of Product Characteristics, as doctors
are able to make an informed decision based on your medical history. We would
therefore suggest that you discuss this matter further with your doctor.
REFERENCES
1. Evorel Conti SPC (October 2019)